Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors (ETOILE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02838602

Recruitment Status : Recruiting

First Posted : July 20, 2016

Last Update Posted : September 2, 2021

See Contacts and Locations

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Hospices Civils de Lyon

Study Description

Brief Summary:

This is a transnational prospective randomized trial comparing definitive carbon ion therapy versus photon or combined photon and protontherapy as standard treatment for unresectable or macroscopically uncompleted resected radioresistant tumors. Eligible tumors are axial chordoma (except of base of skull), adenoid cystic carcinoma of head and neck (except of trachea) and sarcomas of any site (except chondrosarcoma of the skull base), non previously irradiated and without pre-planned surgery or chemotherapy after the clinical trial procedure. Randomization is balanced 1 for 1. Patients of the experimental arm are treated in carbon ions centers in Europe and patients of the standard arm are treated in France in their closest participating radiotherapy center. An accrual of 250 patients is needed and an absolute difference of 20% of relapse free survival at five years is awaited. The main endpoint is the progression free survival at five years. The trial is supported by the French program of clinical research and the national health insurance. Two associated studies are carried out: a radiobiological one looking for radioresistance markers in the sarcomas biopsies, and the second one is about medico economics.

Condition or disease	Intervention/treatment	Phase
Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma	Radiation: Carbon ions therapy Radiation: Advanced external radiotherapy by Xrays or protons	Not Applicable

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	250 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Transnational Randomized Study Comparing Carbon Ions Therapy Versus Conventional Radiotherapy - Including Protontherapy - for the Treatment of Radioresistant Tumors
Actual Study Start Date :	December 23, 2017
Estimated Primary Completion Date :	December 23, 2026
Estimated Study Completion Date :	December 23, 2026

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Chordoma

MedlinePlus related topics: Adenoids

Genetic and Rare Diseases Information Center resources: Soft Tissue Sarcoma Adenoid Cystic Carcinoma Chordoma

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Carbon ions therapy Radical and exclusive carbon ions radiotherapy	Radiation: Carbon ions therapy External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center
Active Comparator: Conventional radiotherapy Radical radiotherapy by Xrays and / or protons	Radiation: Advanced external radiotherapy by Xrays or protons Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy

Outcome Measures

Primary Outcome Measures :

Progression free survival (PFS) [ Time Frame: up to 5 years or loss of follow-up ]
Starting point for PFS measurement is the randomization date

Secondary Outcome Measures :

Grades of the CTCAE-V4.02 classification [ Time Frame: up to 5 years or loss of follow-up ]
Tolerance
EQ-5D questionnaire [ Time Frame: up to 5 years or loss of follow-up ]
Quality of life
Local progression free survival [ Time Frame: up to 5 years or loss of follow-up ]
takes account of the local progression of the tumor in the planning target volume (PTV)
Metastases free survival [ Time Frame: up to 5 years or loss of follow-up ]
takes account of any site of relapse outside of the PTV
Overall survival [ Time Frame: up to 5 years or loss of follow-up ]
delay of death of any cause accounted starting from randomization

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

age ≥ 18 years
No severe comorbidity, life expectancy above 10 years
Unresectable or inoperable or R2 resection of the tumor
Eligible radioresistant tumor according to the limitative list as following:
- adenoid cystic carcinoma of head and neck (larynx and trachea excluded)
- soft tissue sarcoma
- pleomorphic rhabdomyosarcoma only (alveolar and embryonal forms excluded)
- retroperitoneal sarcoma under condition of technical feasibility (movement)
- osteosarcoma of any grade and localisation (Ewing excluded)
- chondrosarcoma (except of skull base) OMS grade >= 2
- chordoma axial skeleton or pelvis (except of skull base)
- angiosarcoma
Absence of epidermal invasion (a hypodermic invasion is accepted with fixity of cutaneous plan but not true epidermal permeation)
Larger volume to be irradiated (PTV) less than 25 cm
ECOG Performance Status ≤ 2 or Karnovsky index ≥ 60
no pregnancy of possibility of pregnancy during the treatment
having an health insurance
signature of a written informed consent
validation of the randomization criteria: namely, a carbon ions therapy indication assessed by the medical team of a hadrontherapy center and able to by treated within two month from registration.

Exclusion Criteria:

Complete macroscopic or microscopic surgical resection (R0 or R1)
previous irradiation in the volume to be treated
metastatic disease
disease not candidate to a curative approach (example accelerated progressive diseaseresistant to nay medical treatment especially for sarcoma)
any contra-indication to undergo a radiation therapy by Xray or particle therapy
planned surgery or chemotherapy to take place after completion of radiotherapy (example : absence of enough space between an organ risk and the target volume (at least 5 mm) except the possibility of a spacer insertion)
planned surgery or chemotherapy after radiotherapy
Presence in the target volume of metallic material which cannot be removed (carbon fibres matreial authorized)
history of concomittant (except in situ cervix carcinoma; or any cured basocellular cutaneous cancer tor any cured cancer with no sign of relapse during 5 years))
impossible follow-up over 5 years

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02838602

Contacts

Layout table for location contacts

Contact: Pascal POMMIER, MD	(0)4 78 78 51 66 ext +33	pascal.pommier@lyon.unicancer.fr

Locations

Show 21 study locations

Layout table for location information

France
CHU Amiens - Hôpital Sud	Recruiting
Amiens, France, 80054
Contact: Claude KRZISCH, MD
Principal Investigator: Claude KRZISCH, MD
Radiothérapie, CLCC François Baclesse	Recruiting
Caen, France, 14076
Contact: Juliette THARIAT, MD
Principal Investigator: Juliette THARIAT, MD
Sub-Investigator: Dinu STEFAN, MD
Sub-Investigator: Delphine LEROUGE, MD
Sub-Investigator: Bernard GERY, MD
Sub-Investigator: Laura MOISE, MD
Sub-Investigator: Sabine NOAL, MD
Sub-Investigator: Jacques BALOSSO, MD
Radiothérapie, CRLCC Jean Perrin	Not yet recruiting
Clermont-Ferrand, France, 63011
Contact: Fanny MARTIN
Principal Investigator: Fanny MARTIN, MD
Sub-Investigator: Michel LAPEYRE, MD
Sub-Investigator: Jessica MIROIR, MD
Radiothérapie, CRLCC GF Leclerc	Recruiting
Dijon, France, 21034
Contact: Gilles TRUC, MD 03.80.73.75.18
Principal Investigator: Gilles TRUC, MD
Sub-Investigator: Noémie VULQUIN, MD
Sub-Investigator: David THIBOUW, MD
Sub-Investigator: Caroline AMOYAL, MD
Radiothérapie, Hôpital A. Michallon, CHU de Grenoble	Recruiting
Grenoble, France, 38043
Contact: Camille, Olivier VERRY, MD 04.76.76.54.35
Principal Investigator: Camille, Olivier VERRY, MD
Sub-Investigator: Julie VILLA, MD
Sub-Investigator: Jacques BALOSSO, MD
Sub-Investigator: Carole IRIART, MD
Sub-Investigator: Violaine BRUN-BARONNAT, MD
Radiothérapie, CRLCC Oscar Lambret	Recruiting
Lille, France, 59020
Contact: Xavier MIRABEL, MD 03.20.29.55.98
Principal Investigator: Xavier MIRABEL, MD
Sub-Investigator: Raphaëlle MOUTTET-AUDOUARD, MD
Sub-Investigator: Abel CORDOBA, MD
Sub-Investigator: Xavier LIEM, MD
Sub-Investigator: David PASQUIER, MD
Radiothérapie, CRLCC Léon Bérard	Recruiting
Lyon, France, 69373
Contact: Pascal POMMIER, MD (0)4 78 78 51 66 ext +33 pascal.pommier@lyon.unicancer.fr
Principal Investigator: Pascal POMMIER, MD
Sub-Investigator: Marie-Pierre SUNYACH, MD
Sub-Investigator: Vincent GREGOIRE, MD
Radiothérapie, CRLCC Institut Paoli Calmettes	Not yet recruiting
Marseille, France, 13009
Contact: Laurence MOUREAU-ZABOTTO, MD 04.91.22.36.37
Principal Investigator: Laurence MOUREAU-ZABOTTO, MD
Radiothérapie, Institut Régional du Cancer Montpellier, ICM Val d'Aurelle	Recruiting
Montpellier, France, 34298
Contact: Pierre BOISSELIER, MD
Principal Investigator: Pierre BOISSELIER, MD
Pôle de radiothérapie, Centre Antoine-Lacassagne	Recruiting
Nice, France, 06189
Contact: Alexander FALK, MD
Principal Investigator: Alexander FALK, MD
Sub-Investigator: Jérôme DOYEN, MD
Sub-Investigator: Pierre-Yves BONDIAU, MD
Sub-Investigator: Karen BENEZERY, MD
Radiothérapie, CHU Pitié-Salpétrière	Not yet recruiting
Paris, France, 75013
Contact: Loïc FEUVRET 01.42.17.81.71
Principal Investigator: Loïc FEUVRET, MD
Institut Curie, site Hôpital de Paris et site d'Orsay (Centre de protonthérapie)	Not yet recruiting
Paris, France, 75231
Contact: Rémi DENDALE, MD
Principal Investigator: Rémi DENDALE, MD
Sub-Investigator: Claire ALAPETITE, MD
Radiothérapie, Hôpital de Haut Lévêque, CHU Bordeaux	Not yet recruiting
Pessac, France, 33604
Contact: Charles DUPIN, MD
Principal Investigator: Charles DUPIN, MD
Sub-Investigator: Huchet AYMERI, MD
Radiothérapie, CRLCC Institut Jean Godinot	Recruiting
Reims, France, 51726
Contact: Stéphanie SERVAGI-VERNAT, MD
Principal Investigator: Stéphanie SERVAGI-VERNAT, MD
Centre Eugene Marquis	Not yet recruiting
Rennes, France, 35000
Contact: Joël CASTELLI, MD
Principal Investigator: Joël CASTELLI, MD
Radiothérapie, CRLCC René Gauducheau	Not yet recruiting
Saint-Herblain, France, 44805
Contact: Augustin MERVOYER, MD 02.40.67.99.30
Principal Investigator: Augustin MERVOYER, MD
Sub-Investigator: Nadia WIAZZANE, MD
Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirtz	Recruiting
St Priest en Jarez, France, 42270
Contact: Nicolas MAGNE, MD
Principal Investigator: Nicolas MAGNE, MD
Sub-Investigator: Amel REHAILIA-BLANCHARD, MD
Sub-Investigator: Grégoire PIGNE, MD
Radiothérapie, CRLCC Paul Strauss	Recruiting
Strasbourg, France, 67065
Contact: Georges NOEL, MD 03.88.25.24.71
Principal Investigator: Georges NOEL, MD
Institut universitaire du cancer de Toulouse - Oncopole, Institut Claudius Regaud	Recruiting
Toulouse, France, 31059
Contact: Anne DUCASSOU, MD
Principal Investigator: Anne DUCASSOU, MD
Principal Investigator: Anne LAPRIE, MD
Sub-Investigator: Martine DELANNES, MD
Radiothérapie, Institut de Cancérologie de Lorraine Alexis Vautrin	Recruiting
Vandœuvre-lès-Nancy, France, 54500
Contact: Guillaume VOGIN, MD 03.83.59.84.27
Principal Investigator: Guillaume VOGIN, MD
Sub-Investigator: Sophie RENARD, MD
Radiothérapie, Institut Gustave Roussy	Not yet recruiting
Villejuif, France, 94805
Contact: Cécile LE PECHOUX, MD 01.42.11.42.11
Principal Investigator: Cécile LE PECHOUX, MD
Sub-Investigator: Stéphanie BOLLE, MD

Sponsors and Collaborators

Hospices Civils de Lyon

Investigators

Layout table for investigator information

Principal Investigator:	Pascal POMMIER, MD	Centre Leon Berard

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Balosso J, Febvey-Combes O, Iung A, Lozano H, Alloh AS, Cornu C, Herve M, Akkal Z, Lievre M, Plattner V, Valvo F, Bono C, Fiore MR, Vitolo V, Vischioni B, Patin S, Allemand H, Gueyffier F, Margier J, Guerre P, Chabaud S, Orecchia R, Pommier P. A randomized controlled phase III study comparing hadrontherapy with carbon ions versus conventional radiotherapy - including photon and proton therapy - for the treatment of radioresistant tumors: the ETOILE trial. BMC Cancer. 2022 May 23;22(1):575. doi: 10.1186/s12885-022-09564-7.

Layout table for additonal information

Responsible Party:	Hospices Civils de Lyon
ClinicalTrials.gov Identifier:	NCT02838602
Other Study ID Numbers:	2012-760
First Posted:	July 20, 2016 Key Record Dates
Last Update Posted:	September 2, 2021
Last Verified:	September 2021

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Hospices Civils de Lyon:


carbon ions therapy radiotherapy radioresistant tumors cancer randomized trial

Additional relevant MeSH terms:

Layout table for MeSH terms

Carcinoma, Adenoid Cystic Chordoma Neoplasms Neoplasms by Histologic Type	Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms, Germ Cell and Embryonal

To Top